title: FDA-approved preventative therapies for MS: first-line agents.
abstract: Relapsing-remitting multiple sclerosis is highly variable in its presentation and disease course. The approach to initiating first-line preventative therapies must focus on individualizing treatment strategies. Careful discussion of available treatment options and appropriate expectations regarding outcomes is important to ensure a successful start. Early treatment is recommended, as is on-going monitoring of patients who may choose to forego therapy.
authors: Virginia Mason Multiple Sclerosis Center, PO Box 900, Seattle, WA 98101, USA. Mariko.Kita@vmmc.org
authors: Mariko
authors: M
authors: Kita
mesh_terms: D017277:Drug Approval; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000517:prevention & control*; D010455:Peptides / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards
chemical_list: D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons